Skip to content

Candidate gene association study of analgesic effects of sufentanil in Chinese Han women undergoing laparoscopy

Candidate gene association study of analgesic effects of sufentanil in Chinese Han women undergoing laparoscopy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089626
Enrollment
Unknown
Registered
2024-09-12
Start date
2024-09-12
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Sponsors

The Third Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1. 200 patients who underwent elective laparoscopic surgery in our hospital, women aged 20-59 years old, were selected; 2. American Society of Anesthesiologists (ASA) class I-III; hepatic function Child grade A; 3 Body mass index (BMI) 18-28; 4 Proposed to perform gynecological systemic surgery under general anesthesia laparoscopy, with an operating time of 60-120 minutes; 5 Can communicate effectively, can complete postoperative pain assessment after training, agree and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1 Serious cardiovascular diseases, such as uncontrolled hypertension and diabetes mellitus, serious respiratory diseases, and serious liver and kidney function abnormalities; 2 History of chronic pain, history of mental illness, long-term smoking, alcoholism; 3. History of allergy to fentanyl analogs or long-term use of analgesics; 4 Pregnant and lactating women; 5 Taking hepatic enzyme inducers, inhibitors, or foods that induce/inhibit hepatic enzyme expression within 1 month before surgery; 6, Tricyclic antidepressants, monoamine oxidase inhibitors within 2 weeks before surgery; 7, Other conditions that the investigator considers inappropriate for participation in this clinical study.

Design outcomes

Primary

MeasureTime frame
drug half-life (t 1/2);

Secondary

MeasureTime frame
blood concentration;

Countries

China

Contacts

Public ContactXiaoyong Wei

Third Affiliated Hospital of Zhengzhou University

yyryyz222108@126.com+86 130 8366 5959

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026